<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; companies</title>
	<atom:link href="http://www.tapanray.in/tag/companies/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>From Share-of-Voice to Share-of-Outcomes: How Indian Pharma Is Rewriting Marketing</title>
		<link>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing</link>
		<comments>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/#comments</comments>
		<pubDate>Sun, 07 Sep 2025 07:39:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rewriting]]></category>
		<category><![CDATA[share of outcomes]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10967</guid>
		<description><![CDATA[If you zoom out on India’s pharma market over the past 18 months, one pattern jumps off the page: marketing is no longer just about pushing brands; it’s about owning moments across the care journey - from the first symptom search to &#8230; <a href="http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Navigating Potential US Tariffs: Challenges and AI-Driven Opportunities for Indian Pharma</title>
		<link>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma</link>
		<comments>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 09 Aug 2025 08:09:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[challenged]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10955</guid>
		<description><![CDATA[India’s pharmaceutical industry, reportedly supplying 47% of US generic drugs and exporting $27.9 billion in FY24, faces the threat of 10-25% US tariffs under a potential Trump policy. Major players like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Aurobindo, reportedly &#8230; <a href="http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revolutionizing Indian Pharma: The Rise of AI and Its Transformative Impact</title>
		<link>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact</link>
		<comments>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/#comments</comments>
		<pubDate>Thu, 13 Mar 2025 11:12:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game-changing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revolutionizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10883</guid>
		<description><![CDATA[I find it fascinating that some well-established consulting firms like E&#38;Y have recently published multiple reports on AI in the pharmaceutical industry. These reports, often released alongside industry events or as part of broader research initiatives, provide valuable insights rather than a &#8230; <a href="http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The AI imperative: Propels Purpose-driven Leaders Revolutionizing Patient Care</title>
		<link>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care</link>
		<comments>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/#comments</comments>
		<pubDate>Fri, 17 May 2024 07:55:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[imperative]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[PDL]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10864</guid>
		<description><![CDATA[The winds of change are blowing in healthcare! Artificial Intelligence (AI) is poised to revolutionize how we deliver quality care to everyone. As a recent ET Healthworld article (March 3, 2024) aptly stated: &#8220;AI and technology are going to be transformative. The only way we can provide &#8230; <a href="http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unleash The Power of RWE in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleash-the-power-of-rwe-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sat, 10 Feb 2024 06:59:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Phaemaceutical]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Real World Evidence]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unleash]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10851</guid>
		<description><![CDATA[An IQIVIA event titled, “RWE in 2024: Recognizing opportunity and demonstrating value with confidence,” held on October 25-26, 2023, made several interesting observations such as: The future of healthcare is being reshaped and RWE is playing an increasing role in revolutionizing patient &#8230; <a href="http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Pharma’s Apathy Towards Digital Marketing’ &#8211; A Misgiving Or Real?</title>
		<link>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real</link>
		<comments>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/#comments</comments>
		<pubDate>Fri, 02 Jun 2023 06:18:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misgiving]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10794</guid>
		<description><![CDATA[As I gather from different sources, an increasing number of Indian pharma companies are increasingly embracing digitalization in their marketing operations, especially after the crippling experience during the Covid lockdown period. They realize the use of digital platforms would be a great &#8230; <a href="http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>This New Engagement Model Garners Significant Rewards For Pharma</title>
		<link>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=this-new-engagement-model-garners-significant-rewards-for-pharma</link>
		<comments>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/#comments</comments>
		<pubDate>Mon, 28 Nov 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10731</guid>
		<description><![CDATA[Last year, on July 26, 2021, I wrote in this blog on gaining a competitive edge with Omnichannel pharma marketing Omnichannel pharma marketing. However, from several recent studies, it appears, it’s still remains in a nascent stage. Most players in the industry haven’t &#8230; <a href="http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
